8-Anti-ipratropium bromide
CAS: 58073-59-9
Ref. 3D-ICA07359
1mg | Ausgelaufen | ||
2mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen |
Produktinformation
- (endo,Anti)-(1)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-isopropyl-8-methyl-8-azoniabicyclo(3.2.1)octane bromide
- 8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide (1:1), (3-endo,8-anti)-
- 8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, (3-endo,8-anti)-
- 8-Azoniabicyclo[3.2.1]octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-, bromide, (endo,anti)-
- Sch 1178
8-Anti-ipratropium bromide is a bronchodilator that belongs to the group of nonsteroidal anti-inflammatory drugs. It is used for the treatment of chronic obstructive pulmonary disease, asthma, and bowel disease. 8-Anti-ipratropium bromide is chemically stable in the presence of light and heat, so it can be delivered via aerosol or nasal formulations. The long-term efficacy of 8-anti-ipratropium bromide has been demonstrated in clinical trials with subjects who have intermittent asthma or are not responsive to other treatments. The drug also has an effect on body mass index (BMI) and blood pressure levels. 8-Anti-ipratropium bromide inhibits the reaction solution by binding to the enzyme acetylcholinesterase at its active site, which prevents its breakdown of acetylcholine. This leads to an accumulation of acetylcholine at muscarinic M1 receptors